/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
  2. 298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2
298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders · Oct 22, 2026

A-Alpha Bio overcomes AI protein design bottlenecks by pooling tens of millions of pre-competitive prospective affinity data points.

Antibody ML models demand data scales exceeding single-company budgets

David Younger explains that training generalizable protein design models requires hundreds of thousands of structural affinity landscapes. Even using high-throughput tools that measure a million affinities at once, funding that volume alone is nearly impossible for one firm, whereas a five-member consortium yields 28 million data points per year.

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2 thumbnail

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Data consortiums incentivize shared experimental designs over federated learning

David Younger argues that federated learning relies on messy historical records and keeps participants isolated. In contrast, pooled data consortiums incentivize members to actively share experimental breakthroughs, because helping peer members design better assays directly increases the quality and volume of data distributed back to everyone.

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2 thumbnail

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Separate upstream precompetitive training data from downstream candidate validation

David Younger divides the data bottleneck into generalizable model training and proprietary candidate validation. Broad target and binder diversity can be generated collaboratively in pre-competitive pools, while validating clinical assets against specific proprietary drug targets remains entirely private and isolated outside the consortium.

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2 thumbnail

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago

Prospective data generation unlocks pharma consortium sharing

David Younger notes that drug companies resist sharing proprietary historical data from past pipeline projects. Instead of asking members to dig into private vaults, A Alpha Bio's consortium focuses purely on forward-looking, pre-competitive experiments where participants design shared datasets with clear visibility before testing begins.

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2 thumbnail

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders·a month ago